TIMP2 and Abnormal renal physiology: These results support thoseof the study by Sapphire.(83)In this large (n = 728) multicenter study of cell cycle arrest, uIGFBP-7 andmetallopeptidase inhibitor 2 (TIMP-2) were both markers of moderate-to-severeAKI (KDIGO stage 2 - 3) within 12 hours of sample collection, and additionally,high values of multiplication of the 2 markers (urinary IGFBP*TIMP-2) doubledthe risk of major adverse kidney events, which were defined by the authors asdeath, the use of RRT or the persistence of renal dysfunction; these findingssuggest a role for this combination of biomarkers as predictors of recovery.